Verona’s RPL554 improves lung function in CF trial
London, UK-based Verona Pharma’s experimental phosphodiesterase therapy has hit targets in a mid-stage trial in patients with cystic fibrosis.
Read More
Tag: FEV1
Vertex secures US approval for Symdeko
US regulators have approved Vertex’ Symdeko, a combination of Kalydeco (ivacaftor) and tezacaftor, to treat certain patients with cystic fibrosis (CF).
Read More
AZ’ triple combo COPD inhaler hits PhIII targets
AstraZeneca recently unveiled top-line trial data backing use of an experimental triple combination therapy being developed for use with its Aerosphere technology in patients with chronic obstructive pulmonary disease (COPD).
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
